ABSTRACT
OBJECTIVE： To evaluate the efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use. METHODS： Retrieved from the Cochrane library， PubMed， Sciencedirect， CNKI， Wanfang database and VIP， RCTs about icotinib or icotinib combined with routine treatment or with other drugs （trial group） versus routine treatment or other drugs （control group） in the treatment of advanced NSCLC were collected. After literature screening， data extraction and literature quality evaluation with Cochrane collaboration bias risk assessment tool 5.1.0， Meta-analysis was performed by using Rev man 5.3 statistical software. RESULTS： A total of 27 RCTs were included， involving 2 345 patients. Results of Meta-analysis showed that response rate [OR＝1.64， 95％CI（1.36， 1.97）， P＜0.000 01] and disease control rate [OR＝1.68， 95％CI（1.39， 2.04）， P＜0.000 01] in trial group were significantly higher than control group； the incidence of ADR in trial group [OR＝0.59， 95％CI（0.48， 0.72）， P＜0.000 01] was significantly lower than control group. CONCLUSIONS： Icotinib shows good efficacy and safety in the treatment of advanced NSCLC.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of recombinant human endostatin(rh-endostatin)com-bined with CT-guided percutaneous microwave ablation in the treatment of non-small cell lung cancer(NSCLC)complicat-ed with chronic obstructive pulmonary disease (COPD). METHODS:A total of 80 cases of NSCLC complicated with COPD were selected from our hospital during Feb. 2014-Feb. 2016,and then divided into control group and observation group according to random number table,with 40 cases in each group. Control group was treated by CT-guided percutane-ous microwave ablation. Observation group was additionally given rh-endostatin injection 7.5 mg/m2,once a day,d1-14, added into 500 mL 0.9％ sodium chloride injection,ivgtt lasting for 4 h,for consecutive 14 d,on the basis of control group;7 d later,next course was performed. A treatment course lasted for 21 d,and they received 4 courses of treat-ment. Survival time,clinical efficacy as well as KPS score and lung function indexes before and after treatment,the oc-currence of ADR were compared between 2 groups. RESULTS:Median survival time of observation group(19.8 months) was significantly longer than that of control group(15.2 months),and total response rate of observation group(72.5％) was significantly higher than that of control group (55.0％),with statistical significance (P0.05). After treat-ment,KPS score and above lung function indexes levels of 2 groups were increased significantly,and those of observa-tion group were significantly higher than those of control group,with statistical significance (P0.05). CONCLUSIONS:rh-endostatin combined with CT-guided percutaneous microwave ablation in the treatment of NSCLC complicated with COPD show good clinical efficacy with less ADR,and can significantly improve lung function and quality of life.